BNTC | Benitec Biopharma Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	11.41 - 12.40
52 Week Range	2.6900 - 13.29
Beta	0.45
Implied Volatility	439.85%
IV Rank	N/A
Day's Volume	400,947
Average Volume	43,901
Shares Outstanding	23,216,400
Market Cap	264,899,124
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-06-24

Valuation
Profitability
Growth
Health
P/E Ratio	-3.88
Forward P/E Ratio	N/A
EPS	-2.94
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	16
Country	USA
Website	BNTC

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC's peers: ADIL, ALRN, AVTX, BPTH, CBIO, DFFN, CAPR, NXTC, EFTR, LABP, APGN, NAVB, ANGN, AMTI, VIRI, ZURA, ZVSA, ONCR, APLM, SGTX, CLRB, SLNO, XTLB

*Chart delayed

Analyzing fundamentals for BNTC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see BNTC Fundamentals page.

Watching at BNTC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on BNTC Technicals page.